<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04993378</url>
  </required_header>
  <id_info>
    <org_study_id>CGOG-EV-1001</org_study_id>
    <nct_id>NCT04993378</nct_id>
  </id_info>
  <brief_title>Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy</brief_title>
  <official_title>A Clinical Study Initiated by Investigator:Prospectively Predict the Efficacy of Precise Treatment of Gastrointestinal Tumors Based on Peripheral Blood Multi-omics Liquid Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shen Lin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To vertify the function of EV-score on predicting &amp; monitoring immunotherapeutic outcomes of&#xD;
      GC&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our previous work identified four plasma EV-derived proteins and combined them to generate a&#xD;
      signature score that robustly predicting immunotherapeutic outcomes at baseline and&#xD;
      dynamically monitoring disease progressions along with the whole treatment.&#xD;
&#xD;
      Hence in this stuty, we plan to recruit a prospective cohort to support our conclusions, and&#xD;
      provide possible method to realize predicting and monitoring immunotherapeutic outcomes of&#xD;
      GC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Actual">April 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>EV-Score</measure>
    <time_frame>EV-Score was detected, analysis and reported at the baseline of the treatment.</time_frame>
    <description>EV-Score was calculated by the expression level of four tumor-associated proteins on plasma EV</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival significance of EV-Score</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Analysis patients' survival with different EV-Score.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Advanced Gastric Adenocarcinoma</condition>
  <condition>Immunotherapy</condition>
  <arm_group>
    <arm_group_label>GC patients receiving immunotherapy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EV-array</intervention_name>
    <description>Collect peripheral blood sample of 40 gastric cancer patients pre-treatment. Blood samples will be transferred to central lab to detect EV-score by EV-array. Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST.&#xD;
Clinical data, including tumor stage, metastastic organ, regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.</description>
    <arm_group_label>GC patients receiving immunotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients in this study were enrolled by the Department of gastrointestinal oncology,&#xD;
        Peking University Cancer Hospital &amp; Institute for conventional therapy or clinical trials&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Having signed informed consent&#xD;
&#xD;
          -  Age≥ 18 years old&#xD;
&#xD;
          -  Histologically confirmed gastric adenocarcinoma&#xD;
&#xD;
          -  Unresectable recurrent or metastatic disease&#xD;
&#xD;
          -  Measurable disease according to the RECIST criteria&#xD;
&#xD;
          -  Life expectancy of ≥3 month&#xD;
&#xD;
          -  No prior chemotherapy of the study more than 4 weeks&#xD;
&#xD;
          -  Immunotherapy regimens were included in the treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other previous malignancy within 5 year&#xD;
&#xD;
          -  Surgery (excluding diagnostic biopsy) within 4 weeks prior to study&#xD;
&#xD;
          -  Pregnancy or lactation period&#xD;
&#xD;
          -  Legal incapacity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking University Cancer Hospital &amp; Institute</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lin shen, MD</last_name>
      <phone>(86)10-88196175</phone>
      <email>lin100@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>lin shen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>cheng zhang, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>xiaotian zhang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>August 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>Director of GI oncology Affiliation: Peking University</investigator_title>
  </responsible_party>
  <keyword>plasma-based liquid biopsy protein biomarker</keyword>
  <keyword>extracellular vesicles</keyword>
  <keyword>protein biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

